On Jul. 21, 2020, Mesa Biotech announced it had been awarded a contract up to $15.4 million from the NIH Rapid Acceleration of Diagnostics program for its Acculaﾙ SARS-CoV-2 Test, which gives COVID-19 diagnostic results in 30 minutes at the point of care.

The RADx program was established to extend the range and increase the availability of diagnostic tests for SARS-CoV-2 a critical component to safely getting Americans back together, including in the workplace, in schools and in lifeﾒs many venues.